No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits ...

Novo Nordisk, the maker of the blockbuster diabetes drug Ozempic, is at the center of a brewing legal storm. Once celebrated ...

Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ...

Novo Nordisk A/S said it has implemented a global hiring freeze as the Danish maker of weight-loss drugs seeks to cut costs ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.

The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a form of liver disease.

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.